Gag (18-26) [Human immunodeficiency virus type 1] acetyl/amide – Antimicrobial Peptides – AMP

CD8+ T-cell (cytotoxic T lymphocyte (CTL)) responses are important in the control of viral replication. Inducing a sustained HIV-1 specific CD8+ T-cell response is the target for vaccine development by using conserved HIV-1 epitopes. The HIV gag gene encodes p17 and p24. P17 Gag is a matrix protein that is vital to HIV life cycle, use of p17 Gag epitopes is a possibility for HIV therapies. P17 Gag targets viral RNA to the nucleus and Gag polyproteins to the cell membrane- p17 Gag accumulates in the extracellular space of tissue while interacting with receptors on various cell types to deregulate cell function. CTL recognition epitope of p17 Gag is identified as residues 77-85 to activate the immune response. Within Gag p17 is the conserved/persistently recognised epitope KIRLRPGGK (amino acids 18-26). This sequence has been used as an effective epitope in immunological assays to assess CTL response work has also shown patients targeting conserved or variable Gag epitopes including Gag p17 (18-26) effects the strength of CD8+ T-cell response and disease progression.

Technical specification

Price